{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T20:23:54Z","timestamp":1789849434954,"version":"4.0.1"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejinme.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Internal Medicine"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1016\/j.ejim.2019.05.020","type":"journal-article","created":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T11:00:43Z","timestamp":1558609243000},"page":"1-8","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"special_numbering":"C","title":["New oncologic emergencies: What is there to know about inmunotherapy and its potential side effects?"],"prefix":"10.1016","volume":"66","author":[{"given":"Arantzazu","family":"Barqu\u00edn-Garc\u00eda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4616-0598","authenticated-orcid":false,"given":"Javier","family":"Molina-Cerrillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5899-6125","authenticated-orcid":false,"given":"Pilar","family":"Garrido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Garcia-Palos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfredo","family":"Carrato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Alonso-Gordoa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejim.2019.05.020_bb0005","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1093\/annonc\/mds256","article-title":"Immuno-oncology: Understanding the function and dysfunction of the immune system in cancer","volume":"23","author":"Finn","year":"2012","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ejim.2019.05.020_bb0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","article-title":"Oncology meets immunology: The cancer-immunity cycle","volume":"39","author":"Chen","year":"2013","journal-title":"Immunity."},{"key":"10.1016\/j.ejim.2019.05.020_bb0015","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/S0092-8674(05)80055-8","article-title":"Costimulation of T lymphocytes: the role of CD28, CTLA-4, and B7\/BB1 in interleukin-2 production and immunotherapy","volume":"71","author":"Schwartz","year":"1992","journal-title":"Cell."},{"key":"10.1016\/j.ejim.2019.05.020_bb0020","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/j.1600-065X.2009.00770.x","article-title":"CD28 and CTLA-4 coreceptor expression and signal transduction","volume":"229","author":"Rudd","year":"2009","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.ejim.2019.05.020_bb0025","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1146\/annurev.immunol.26.021607.090331","article-title":"PD-1 and its ligands in tolerance and immunity","volume":"26","author":"Keir","year":"2008","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.ejim.2019.05.020_bb0030","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/j.1600-065X.2010.00923.x","article-title":"The PD-1 pathway in tolerance and autoimmunity","volume":"236","author":"Francisco","year":"2010","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.ejim.2019.05.020_bb0035","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med."},{"key":"10.1016\/j.ejim.2019.05.020_bb0040","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus Ipilimumab in Advanced Melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med."},{"key":"10.1016\/j.ejim.2019.05.020_bb0045","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med."},{"key":"10.1016\/j.ejim.2019.05.020_bb0050","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non\u2013small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N Engl J Med."},{"key":"10.1016\/j.ejim.2019.05.020_bb0055","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous cell non\u2013small-cell lung cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N Engl J Med."},{"key":"10.1016\/j.ejim.2019.05.020_bb0060","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","article-title":"Pembrolizumab for the treatment of non\u2013small-cell lung cancer","volume":"372","author":"Garon","year":"2015","journal-title":"N Engl J Med."},{"key":"10.1016\/j.ejim.2019.05.020_bb0065","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0140-6736(16)32517-X","article-title":"Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial","volume":"389","author":"Rittmeyer","year":"2017","journal-title":"Lancet."},{"key":"10.1016\/j.ejim.2019.05.020_bb0070","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","article-title":"Nivolumab versus everolimus in advanced renal cell carcinoma","volume":"373","author":"Motzer","year":"2015","journal-title":"N Engl J Med."},{"key":"10.1016\/j.ejim.2019.05.020_bb0075","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","article-title":"Nivolumab for recurrent squamous-cell carcinoma of the head and neck","volume":"375","author":"Ferris","year":"2016","journal-title":"N Engl J Med."},{"key":"10.1016\/j.ejim.2019.05.020_bb0080","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","article-title":"Pembrolizumab as second-line therapy for advanced urothelial carcinoma","volume":"376","author":"Bellmunt","year":"2017","journal-title":"N Engl J Med."},{"key":"10.1016\/j.ejim.2019.05.020_bb0085","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/S0140-6736(17)33297-X","article-title":"Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial","volume":"391","author":"Powles","year":"2018","journal-title":"Lancet."},{"key":"10.1016\/j.ejim.2019.05.020_bb0090","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","article-title":"Overall survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"377","author":"Wolchok","year":"2017","journal-title":"N Engl J Med."},{"key":"10.1016\/j.ejim.2019.05.020_bb0095","doi-asserted-by":"crossref","first-page":"3851","DOI":"10.1200\/JCO.2016.72.1985","article-title":"Safety and efficacy of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma: The CheckMate 016 Study","volume":"35","author":"Hammers","year":"2017","journal-title":"J.Clin. Oncol."},{"key":"10.1016\/j.ejim.2019.05.020_bb0100","author":"National Cancer Institute"},{"key":"10.1016\/j.ejim.2019.05.020_bb0105","first-page":"473","article-title":"Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination","volume":"13","author":"Boutros","year":"2016","journal-title":"Nat Rev."},{"key":"10.1016\/j.ejim.2019.05.020_bb0110","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med."},{"key":"10.1016\/j.ejim.2019.05.020_bb0115","doi-asserted-by":"crossref","first-page":"76","DOI":"10.14694\/EdBook_AM.2015.35.76","article-title":"Managing immune checkpoint-blocking antibody side effects","volume":"35","author":"Postow","year":"2015","journal-title":"Am Soc Clin Oncol Educ Book."},{"key":"10.1016\/j.ejim.2019.05.020_bb0120","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1200\/JCO.2012.41.6750","article-title":"Management of immune-related adverse events and kinetics of response with ipilimumab","volume":"30","author":"Weber","year":"2012","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.ejim.2019.05.020_bb0125","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdx225","article-title":"Management of toxicities from immunotherapy ESMO Clinical Practice Guidelines for diagnosis, treatment and follow up","author":"Haanen","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejim.2019.05.020_bb0130","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejim.2019.05.020_bb0135","series-title":"Management of immunotherapy-related toxicities (immune checkpoint inhibitor-related toxicities)","author":"Thompson","year":"2018"},{"key":"10.1016\/j.ejim.2019.05.020_bb0140","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1001\/jamaoncol.2016.1051","article-title":"Treatment of the immune-related adverse effects of immune checkpoint inhibitors: a review","volume":"2","author":"Friedman","year":"2016","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.ejim.2019.05.020_bb0145","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ctrv.2016.02.001","article-title":"Management of toxicities of immune checkpoint inhibitors","volume":"44","author":"Spain","year":"2016","journal-title":"Cancer Treat Rev."},{"key":"10.1016\/j.ejim.2019.05.020_bb0150","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2014-000014","article-title":"Glucocorticoid-induced osteoporosis","volume":"1","author":"Briot","year":"2015","journal-title":"RMD Open."},{"key":"10.1016\/j.ejim.2019.05.020_bb0155","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1097\/CCO.0000000000000290","article-title":"Dermatologic complications of antiPD-1\/PD-L1 immune checkpoint antibodies","volume":"28","author":"Sibaud","year":"2016","journal-title":"Curr Opin Oncol."},{"key":"10.1016\/j.ejim.2019.05.020_bb0160","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jaad.2014.02.035","article-title":"Ipilimumab in patients with cancer and the management of dermatologic adverse events","volume":"71","author":"Lacouture","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ejim.2019.05.020_bb0165","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/cup.12858","article-title":"Diverse types of dermatologic toxicities from immune checkpoint blockade therapy","volume":"44","author":"Curry","year":"2017","journal-title":"J Cutan Pathol"},{"key":"10.1016\/j.ejim.2019.05.020_bb0170","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/S1470-2045(16)30126-7","article-title":"Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial","volume":"17","author":"Weber","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ejim.2019.05.020_bb0175","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1111\/apt.13281","article-title":"Systematic review: colitis associated with anti-CTLA-4 therapy","volume":"42","author":"Gupta","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.ejim.2019.05.020_bb0180","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1056\/NEJMc1505197","article-title":"Anti-PD-1-related pneumonitis during cancer immunotherapy","volume":"373","author":"Nishino","year":"2015","journal-title":"N Engl J Med."},{"key":"10.1016\/j.ejim.2019.05.020_bb0185","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1001\/jamaoncol.2016.2453","article-title":"Incidence of programmed cell death 1 inhibitorrelated pneumonitis in patients with advanced cancer: A systematic review and meta-analysis","volume":"2","author":"Nishino","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ejim.2019.05.020_bb0190","article-title":"Clinical outcomes in patients with metastatic lung cancer treated with PD-1\/PD-L1 inhibitors and thoracic radiotherapy","author":"Hwang","year":"2017","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.ejim.2019.05.020_bb0195","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S1470-2045(15)70054-9","article-title":"Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial","volume":"16","author":"Rizvi","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ejim.2019.05.020_bb0200","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1200\/JCO.2016.68.2005","article-title":"Pneumonitis in patients treated with anti-programmed death-1\/programmed death ligand 1 therapy","volume":"35","author":"Naidoo","year":"2017","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.ejim.2019.05.020_bb0205","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1097\/PAS.0000000000000453","article-title":"Ipilimumab-associated hepatitis: clinicopathologic characterization in a series of 11 cases","volume":"39","author":"Johncilla","year":"2015","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.ejim.2019.05.020_bb0210","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1634\/theoncologist.2016-0055","article-title":"Management of adverse events following treatment with anti-programmed death-1 agents","volume":"21","author":"Weber","year":"2016","journal-title":"The Oncologist."},{"key":"10.1016\/j.ejim.2019.05.020_bb0215","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1097\/CCO.0000000000000293","article-title":"Endocrinological side-effects of immune checkpoint inhibitors","volume":"28","author":"Torino","year":"2016","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.ejim.2019.05.020_bb0220","doi-asserted-by":"crossref","first-page":"230ra45","DOI":"10.1126\/scitranslmed.3008002","article-title":"Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody","volume":"6","author":"Iwama","year":"2014","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.ejim.2019.05.020_bb0225","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1210\/jc.2012-4075","article-title":"Endocrine side effects induced by immune checkpoint inhibitors","volume":"98","author":"Corsello","year":"2013","journal-title":"J Clin Endocrinol Metab."},{"key":"10.1016\/j.ejim.2019.05.020_bb0230","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.ejca.2016.02.024","article-title":"Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy","volume":"60","author":"Zimmer","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejim.2019.05.020_bb0235","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.116.003514","article-title":"Acute lymphocytic myocarditis with anti-PD-1 antibody nivolumab","volume":"9","author":"Tadokoro","year":"2016","journal-title":"Circ Heart Fail."},{"key":"10.1016\/j.ejim.2019.05.020_bb0240","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","article-title":"Fulminant myocarditis with combination immune checkpoint blockade","volume":"375","author":"Johnson","year":"2016","journal-title":"N Engl J Med."},{"key":"10.1016\/j.ejim.2019.05.020_bb0245","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.ejca.2017.11.018","article-title":"Arterial thrombosis and anti-PD-1 blockade","volume":"91","author":"Boutros","year":"2018","journal-title":"Eur J Cancer."},{"key":"10.1016\/j.ejim.2019.05.020_bb0250","doi-asserted-by":"crossref","first-page":"2510","DOI":"10.1182\/blood-2018-99-116439","article-title":"Venous Thromboembolism in Cancer Patients Receiving Immunotherapy","volume":"132","author":"Roopkumar","year":"2018","journal-title":"Blood."},{"key":"10.1016\/j.ejim.2019.05.020_bb0255","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.currproblcancer.2016.12.004","article-title":"Renal complications of immune checkpoint blockade","volume":"41","author":"Murakami","year":"2017","journal-title":"Curr Probl Cancer."},{"key":"10.1016\/j.ejim.2019.05.020_bb0260","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1097\/CCO.0000000000000296","article-title":"Ocular and orbital side-effects of checkpoint inhibitors: a review article","volume":"28","author":"Antoun","year":"2016","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.ejim.2019.05.020_bb0265","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s40425-017-0210-0","article-title":"Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy","volume":"5","author":"Shiuan","year":"2017","journal-title":"J Immunotherapy Cancer."},{"key":"10.1016\/j.ejim.2019.05.020_bb0270","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1093\/annonc\/mdx177","article-title":"Lethal aplastic anemia caused by dual immune checkpoint blockade in metastatic melanoma","volume":"28","author":"Helgadottir","year":"2017","journal-title":"Ann Oncol."},{"key":"10.1016\/j.ejim.2019.05.020_bb0275","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1159\/000452296","article-title":"Autoimmune hemolytic anemia as a complication of nivolumab therapy","volume":"9","author":"Palla","year":"2017","journal-title":"Case Rep Oncol."}],"container-title":["European Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620519301785?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620519301785?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T09:28:44Z","timestamp":1760606924000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0953620519301785"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":55,"alternative-id":["S0953620519301785"],"URL":"https:\/\/doi.org\/10.1016\/j.ejim.2019.05.020","relation":{},"ISSN":["0953-6205"],"issn-type":[{"value":"0953-6205","type":"print"}],"subject":[],"published":{"date-parts":[[2019,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New oncologic emergencies: What is there to know about inmunotherapy and its potential side effects?","name":"articletitle","label":"Article Title"},{"value":"European Journal of Internal Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejim.2019.05.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}